a 1 -Adrenoceptor antagonists, have been documented to induce apoptosis and reduce prostate tumor vascularity in benign and malignant prostate cells. The quinazoline based a 1 -antagonists, doxazosin and terazosin but not tamsulosin (a sulphonamide derivative) suppress prostate growth without affecting cell proliferation. These quinazoline-mediated apoptotic effects occur via an a 1 -adrenoceptor independent mechanism potentially involving activation of the TGF-b signal transduction pathway. This review discusses the current knowledge of the action of quinazoline-derived a 1 -adrenoceptor antagonists in the benign and malignant prostate and their potential therapeutic use in the treatment of benign prostatic hyperplasia (BPH) and prostate cancer. Finally, a molecular pathway is proposed for their observed apoptotic function against prostate cells. Increased understanding of the action of these established and clinically accepted agents would provide a basis for the design of safe, effective therapeutic regimens in the treatment of prostatic diseases.
Introduction
At the start of a new millennium, prostatic diseases continue to affect and account for a substantial number of lives in the USA. An estimated one in 11 men will develop a malignant neoplasm of the prostate and approximately 37 000 men will die each year from prostate cancer. 1 For European Community countries, more than 35 000 annual deaths are forecast due to prostate cancer. 2 Prostate cancer mortality results from metastases to the bone and lymph nodes together with progression from androgen-dependent to androgen independent disease. 3 The high mortality associated with these tumors is due to the fact that more than 50% of newly diagnosed patients present with advanced, metastatic disease. 4, 5 Radical prostatectomy, androgen-ablation monotherapy and radiotherapy are considered to be curative for localized disease, 6 -8 but there is no effective treatment for metastatic prostate cancer that increases patient survival. 6 As men approach their sixth decade of life, 50% of them will require treatment for the management of lower urinary tract symptoms (LUTS). This is clinically characterized by enlargement of the prostate and progressive bladder outlet obstruction, with 90% of them having histological evidence of benign prostatic hyperplasia (BPH) 9 by the ninth decade. Hyperplasia of both stromal and glandular components of the ageing prostate is implicated in the development and pathophysiology of BPH.
The high number of men who will be affected by either prostate cancer or BPH and those currently diagnosed with prostatic diseases translates into an imperative need for the immediate development of clinically effective therapeutic modalities. As loss of apoptosis is associated with the development of prostatic diseases, BPH and prostate cancer, 10 re-activation of cell death pathways within the prostate represents an alternative target for pharmacological intervention. Recently, there have been increased efforts toward the design of pharmacological agents that would target the apoptotic component of prostate epithelial cells and significantly improve the therapeutic response of prostate cancer and BPH, while minimizing toxicity. 11 The therapeutic significance of apoptosis in the treatment of prostate cancer emerges from evidence suggesting that like normal prostate epithelial cells, prostate cancer cells maintain sensitivity to androgens and undergo apoptosis in response to androgen withdrawal. 10, 12, 13 The androgen-independent prostate cancer cells still contain an intact apoptotic machinery and can undergo apoptosis in response to hormone independent approaches, 14 such as ionizing radiation and chemotherapeutic agents. 14 -17 During the last decade, a new class of pharmacological drugs, the a-1 adrenoceptor antagonists, has emerged as clinically useful for the long-term management of BPH. This review aims to outline the recently recognized apoptotic actions of these a 1 -antagonists against benign and malignant prostate cancer growth and to discuss potential molecular mechanisms underlying this effect that has been specifically associated with the quinazoline-based a 1 -adrenoceptor antagonists.
Discussion
(1) The a 1 -adrenoceptor connection in the human prostate
The identification of a 1 -adrenoceptors within the smooth muscle element of prostate adenomas, prostatic capsule and bladder neck 18 led to the targeting of these elements for therapeutic purposes. a 1 -Adrenoceptors belong to the superfamily of G-protein coupled adrenergic receptors which mediate actions of endogenous catecholamines (norepinephrine and epinephrine). Two types of a 1 -adrenoreceptors have been identified in the bladder 19, 20 and at the bladder neck and in the prostatic smooth muscle surrounding the urethra. 21 Targeting these receptors as a means of preventing smooth muscle contraction gave rise to a class of medications commonly used to treat LUTS. 22, 23 There are currently four recognized subtypes of a-adrenoceptors identified in the prostate: a 1a , a 1b , a 1d and a 1L . 24 -26 Classically, a 1 -adrenoceptor antagonists have been used to target the stromal smooth muscle cells in the treatment of BPH in order to reduce their tone. The competitive inhibition of catecholamines prevents smooth muscle contraction by interfering with perpetuation of second messenger pathways and subsequently modulating cytoskeletal proteins in prostatic smooth muscle cells. 27 The therapeutic efficacy of a 1 -adrenoreceptor antagonists for the treatment of BPH has been clinically documented and their safety profiles of these a 1 -blockers are now well established as a result of their long-term use as front-line antihypertensive agents. 28 -30 Recent evidence gathered at our center suggests that in addition to decreasing smooth muscle tone, two a 1 -adrenoceptor antagonists, doxazosin and terazosin, induce apoptosis in benign and malignant prostate epithelial cells, as well as prostate smooth muscle cells. 31 -33 The findings that a 1 -adrenoceptor antagonists can induce apoptosis in prostate epithelial cells in clinical specimens of BPH triggered an upsurge of investigations into the mechanism of action of these drugs against prostate cell growth. Our initial clinical observations were in full accord with experimental studies using a mouse model of prostate hyperplasia, in which doxazosin exhibited a potent apoptotic effect against oncogene-induced prostatic growth. 34 In the androgen-independent prostate cancer cells, PC-3 and DU-145 pharmacologically relevant doses of the quinazoline-derived a 1 -antagonists, doxazosin and terazosin (15 -25 mM) resulted in significant induction of apoptosis in vitro. 33 In contrast, tamsulosin, a methoxysulphonamide derived a 1 -adrenoceptor antagonist had no effect on prostate growth. 33 Furthermore, in vivo efficacy studies showed that doxazosin treatment suppressed tumorigenic growth of PC-3 prostate cancer xenografts growing in SCID mice. 33 Confirming support for our data came from another independent study that was recently reported. 35 Although originally designed as antagonists of a 1 -adrenoceptors, recent mechanistic studies have implicated a non-a 1 -adrenoreceptor mediated mechanism of apoptotic action of doxazosin and terazosin in prostate cancer cells. 33 The studies summarized in Table 1 provide a strong argument in support of a growth regulatory effect of a 1 -adrenoceptor antagonists in the prostate and raise the possibility that programmed cell death of prostate cancer cells occurs via an effect mediated by the quinazoline component of the drugs. Interestingly, both doxazosin and terazosin were found to exert a similar apoptotic effect in human breast cancer cells, but not in other human tumor cell lines (such as colon or bladder cancer cells), 33, 36 implying a quinazoline-driven action potentially targeted at hormone-dependent tissues. While one cannot rule out the possibility that this might be prostate specific effect, further investigation is required to establish the organ specificity of this action. In the following sections we will discuss the potential signaling pathways that may underlie such an apoptotic effect specifically directed by the quinazoline-based a 1 -adrenoceptor antagonists in prostate tumor cells.
(2) Induction of prostate apoptosis: the TGF-b signal transduction pathway
Transforming growth factor-b (TGF-b) is a multifunctional cytokine which regulates cell proliferation, extracellular matrix production and degradation, differentiation and modulation of apoptosis. 37 TGF-b is a physiological regulator of prostatic growth 38, 39 via its ability to inhibit prostate epithelial cell proliferation and activate apoptosis in the presence of physiological levels of androgens. 38, 40 Interestingly, TGF-b is overexpressed in the malignant prostate when compared with the normal gland. 41, 42 A molecular basis for this TGF-b ligand elevation in prostate cancer could be accounted for by an increased activation of Raf. 43 The apoptotic process initiated by TGF-b is mediated by complex downstream signaling events that lead to nuclear gene expression. This begins with the formation of a stable heteromeric complex of the TGF-b ligand and its transmembrane receptors TGF-b receptor I (TbRI) and TGF-b receptor II (TbRII) 44 which have intrinsic cytoplasmic serine-threonine kinase domains. 45 TGF-b interacts with TbRII which recruits TbRI into the complex 44 where it becomes phosphorylated, subsequently leading to downstream signaling. 46 TGF-b initiated intracellular signaling events are mediated by the Smad family of coactivators and transcription factors. 47 The importance of these transcription factors in mediating apoptosis of prostate epithelial cells was demonstrated by immunohistochemical analysis of normal prostate and prostate tumors where castration induced apoptosis was associated with increased expression and nuclear accumulation of Smads 2, 3, 4, 6 and 7. 48 Decreased levels of TGF-b receptors are associated with increasing grade in prostate tumors, 49 -51 while enforced expression of TbRII in LNCaP cells restores sensitivity to TGF-b, leading to growth arrest and apoptosis. 52 The intracellular mediators of TGF-b signaling pathway may also be targets for apoptosis driven-pharmacological intervention. In response to TGF-b, the receptor activated Smads 2 and 3 are phosphorylated by the activated TbRI 53 and these receptor activated-Smads upon association with the Co-Smad, Smad4, are subsequently translocated into the nucleus. Smad4 can only translocate to the nucleus while complexed with the RSmads, whereas TGF-b activated Smads can enter the nucleus independently of Smad4. 54 Smad4, originally identified as a candidate tumor suppressor gene, deleted in pancreatic carcinoma locus 4 (DPC4), is lost or inactivated in approximately 40% of pancreatic carcinomas. 55 Additionally, multiple defects in TGF-b signaling pathway partly due to reduced expression and activation of Smad2 has recently been reported in head and neck squamous cell carcinomas. 56 Recent findings from this laboratory link TGF-b signaling with the quinazoline-based induction of prostate apoptosis. Increased levels of TGF-b protein expression in prostatic stromal and epithelial cells undergoing apoptosis was observed in clinical specimens from patients treated with a 1 -blockade, 57 evidence supporting TGF-b upregulation in response to these drugs. One could thus postulate that increased secretion of TGF-b in the response to quinazoline-mediated apoptosis prostate tissue may be attributed to dying cells releasing active TGF-b, as has been reported in apoptotic T-cells that release TGF-b protein without an increase in mRNA level. 58 Indirect support for this concept stems from observations that doxazosin treatment of PC-3 prostate cancer cells does not yield any changes in TGF-b mRNA expression over a 24 h timecourse of apoptosis induction. 42 
(3) Antagonistic signaling pathways of TGF-b mediated apoptotic effects
As previously discussed, several pathways impinge on the TGF-b signaling pathway in vitro and modulate the apoptotic response. The EGFR/PI-3K pathway, 59 PI-3/ Akt pathway, 60,61 EGFR/Ras/MAPK pathway, 62 and the NF-kB pathway 63 play key roles in cellular proliferation and cell survival. These pathways are hyperactivated in a number of human tumors including the prostate cancer. 62 In BPH, increased levels of EGFR and the related HER2/ neu signaling pathways have also been associated with loss of growth control. 64 -66 Downstream elements of the EGFR pathway have inhibitory effects on the Smad elements of the TGF-b signaling, potentially pathway via a Ras mediated mechanism 67 and the transcriptional co-repressor, TGIF. 68 EGFR has also been implicated in the activation of the survival factor NF-kB 69 suggesting multiple mechanisms for mediating cell survival. HER2/neu belongs to the EGFR family of receptor tyrosine kinases and has been implicated in androgen-independent prostate cancer growth by activation of the androgen receptor pathway. 70, 71 The HER2/neu pathway also promotes cell survival through the PI-3/Akt pathway 72 by inactivating the pro-apoptotic protein Bad. 73 Interestingly, the PI-3/ Akt pathway activates the NF-kB transcription factor which mediates several cellular processes including cell growth, inflammatory responses and apoptosis 63 and inhibition of TGF-b signaling by increasing Smad7 expression. 74 NF-kB can be activated by pathogenic sig- nals and proinflammatory cytokines 75 involving the phosphorylation of IkBa, which is subsequently degraded via the ubiquitin pathway. 76 Activation of NF-kB in Blymphocytes upregulates the inhibitory Smad7 and subsequently attenuates TGF-b induced growth inhibition and apoptosis. 77 Conversely, increased IkBa stability and aberrant NF-kB expression mediated by TGF-b in breast cancer cells has been associated with induced apoptosis. 78 This would imply that apoptotic pathways via a crosstalk with TGF-b can antagonize NF-kB activity by upregulating IkBa. Direct support for this concept is derived from studies linking apoptosis of smooth muscle cells to the deactivation of NF-kB. 79 Furthermore, recent molecular analyses revealed that doxazosin upregulates IkBa expression in prostate cancer cells, an event that temporally precedes induction of apoptosis in this system. 80 Taken together, these findings provide an interesting mechanistic insight into the apoptotic effect of quinazolines. Considering the above, it is becoming increasingly evident that there is a functional interplay between diverse intracellular signal transduction pathways and the TGF-b signaling mechanism, that would result in inhibition of the latter. This may occur by inactivation or decreased expression of signal transduction elements, or upregulation of Smad specific inhibitory factors. Thus, removal of these repressive pathways may facilitate normal TGF-b signaling and subsequent apoptosis activation during benign and malignant prostate growth.
(4) Quinazolines as antitumor agents: a molecular insight
Quinazoline based compounds have been studied intensely since they were found to compete with ATP binding to protein tyrosine kinases to inhibit various signaling pathways. The mechanism of action for quinazoline based tyrosine kinase inhibitors (TKI) involves the prevention of the transmembrane tyrosine kinase phosphorylation by competing with ATP binding site on the receptor. 81 A number of quinazoline-based antitumor agents acting as TKI exhibit potent antiproliferative, antiangiogenic or apoptotic effects against several cancer cell types. For instance, the selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, Iressa (ZD1839) inhibits tumorigenicity and angiogenic activity of several cancer cell lines including breast, colon and ovarian and colon cancer xenografts. 82 Another TKI, PKI166 induces apoptosis in endothelial cells, while it decreases growth of pancreatic carcinoma cells. 83 Significantly enough, we recently reported that prostate tumors from patients who underwent treatment with terazosin and doxazosin exhibited increased apoptosis and reduced tissue neovascularization. 84 Considering the apoptotic and potential antiangiogenic effect of terazosin and doxazosin (but not tamsulosin) against prostate cancer cells, one may speculate that the intrinsic quinazoline component may confer partial tyrosine kinase inhibitor activity to these drugs. The chemical structures of the two quinazoline-derived a 1 -adrenoceptor antagonists, doxazosin and terazosin, Growing evidence from this laboratory supports the concept that the mechanism of doxazosin and terazosin action against benign and malignant prostate cells occurs independently of targeting the a 1 -adrenoceptors. 83, 86 It is tempting to propose that the apoptotic effects of these drugs may share mechanistic similarity with other quinazoline-based agents reported in the literature. A novel class of TKI, the 4-aniloquinazolines have apoptotic inducing capabilities. 87 Although the quinazoline based a 1 -adrenoceptor antagonists ( Figure 1 ) were originally designed, to antagonize a 1 -adrenoceptors to mediate their effects, mounting evidence indicates that these agents induce apoptosis independently of an a 1 -adrenoceptor action. 36, 86 We therefore propose that these quinazoline-based a 1 -adrenoceptor antagonists may potentially have some tyrosine kinase activity. Such activity would interfere with the signaling of EGFR, HER2/neu, PI-3K pathways, all of which have previously been shown to have repressive effects on TGF-b signaling. Thus, a model has been proposed to provide a mechanistic basis for the signaling of quinazoline based a 1 -adrenoceptor antagonists against prostatic cell growth (Figure 2) . The rapidly induced expression of the TGF-b regulated gene Smad7, the TGF-b inducible IkBa and p21 in prostate cancer cells after doxazosin treatment, implicates the TGF-b signaling pathway in the execution of the quinazoline apoptotic effect in prostate cells. Considering the existing reports discussed above, it is conceivable that this may feature tyrosine kinase-mediated pathways that facilitate cell survival by inhibiting the TGF-b pathway as illustrated in Figure 2 to quinazoline treatment is currently being investigated. We also propose that antagonism of these overactive tyrosine kinase pathways in prostate cancer and BPH by the quinazoline-based a 1 -adrenoceptor antagonists may, in turn, uncouple the TGF-b pathway from the mitogenic pathways initiated by tyrosine kinases. The temporal gene expression profile of key intracellular and nuclear effectors of TGF-b transduction pathway in normal, benign and malignant prostate epithelial cells in response to quinazoline-based a 1 -adrenoceptor antagonists is currently being characterized, using microarray analysis.
Summary
With the progressive unraveling of the apoptotic processes at the molecular level, the development of pharmacological agents against prostate cancer has become the focus of intense investigations. Considering that apoptosis induction in prostate biopsies from BPH patients was observed over the normal dose range, 31, 32, 57 effective application of these FDA-approved agents the quinazoline-based a 1 -antagonists, may have promising therapeutic effects not only in the long-term management of BPH, but also in prostate cancer, potentially resulting in decreased morbidity. The elucidation of the molecular pathway(s) with which these quinazolinebased drugs induce apoptosis in androgen independent prostate cancer cells (with minimal effect against normal cells) would clearly be beneficial, since it would provide an additional basis for the design of novel, more effective regimens with an established safety and tolerance profile for the effective management of prostatic diseases.
